TCM
GSK icon

Triumph Capital Management’s GSK GSK Stock Holding History

Triumph Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.5K Sell
983
-34
-3% -$1.8K 0.01% 670
2026
Q1 		$56.6K Buy
1,017
+55
+6% +$2.98K 0.01% 608
2025
Q4 		$47.2K Buy
+962
New +$44.9K 0.01% 634
2024
Q1 		– Sell
-12,971
Closed -$485K – 239
2023
Q4 		$485K Sell
12,971
-155
-1% -$5.56K 0.21% 102
2023
Q3 		$480K Buy
13,126
+470
+4% +$16.7K 0.22% 105
2023
Q2 		$456K Sell
12,656
-332
-3% -$11.9K 0.21% 104
2023
Q1 		$462K Buy
12,988
+1,223
+10% +$42.8K 0.24% 82
2022
Q4 		$413K Sell
11,765
-9,840
-46% -$328K 0.22% 108
2022
Q3 		$641K Buy
21,605
+16,868
+356% +$639K 0.35% 64
2022
Q2 		$258K Buy
+4,737
New +$262K 0.14% 158

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Triumph Capital Management's GSK Position: Q2 2026 in Review

Triumph Capital Management reduced its GSK (GSK) stake by 3.3% in Q2 2026, selling an estimated $1.8K and leaving 983 shares worth $51.5K. The position accounts for 0.01% of the portfolio, ranked #670.

Triumph Capital Management first reported a position in GSK in Q2 2022 and has held it in 10 quarters since. The position peaked at $641K in Q3 2022. 235 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Triumph Capital Management held 983 shares of GSK worth $51.5K as of Q2 2026.
  • Triumph Capital Management sold 34 GSK shares in Q2 2026, an estimated $1.8K.
  • GSK made up 0.01% of Triumph Capital Management's portfolio in Q2 2026, its #670 holding.
  • Triumph Capital Management first reported a position in GSK in Q2 2022 and has held it in 10 quarters since.
  • Triumph Capital Management's GSK position peaked at $641K in Q3 2022.
  • 235 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.